Rexahn’s goal is to be a world-class biopharmaceutical company developing and delivering novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Leveraging a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling and nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.
08/03/11
Rexahn Pharmaceuticals' CEO to become CSO; new CEO expected by September21/12/10
Rexahn Pharmaceuticals issued Japanese patent for anti-cancer compound RX-004709/12/10
Rexahn Pharmaceuticals Presents Serdaxin Phase IIa Clinical Data at the American College of Neuropsy22/11/10
Rexahn Pharmaceuticals adds US patent to CNS treatment portfolio09/11/10
Rexahn Pharmaceuticals publishes anti-cancer compounds study in medical journal05/11/10
Rexahn Pharmaceuticals receives more than $800,000 in US govt grants for projects19/10/10
Rexahn Pharmaceuticals rallies on publication of new preclinical data for anti-cancer compounds22/09/10
Rexahn says study shows neuroprotective effects of clavulanic acid, main ingredient in Seradaxin dr08/06/10
Rexahn Pharma hires investment banker Frederick Frank as an independent consultant13/05/10
Rexahn Pharma to Initiate Zoraxel Phase IIb trial for treating erectile dysfunction
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
